Point72 Asset Management L.P. Sells 184,632 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Point72 Asset Management L.P. reduced its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 68.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 84,151 shares of the specialty pharmaceutical company's stock after selling 184,632 shares during the quarter. Point72 Asset Management L.P. owned about 0.14% of Jazz Pharmaceuticals worth $10,363,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. IFP Advisors Inc bought a new stake in Jazz Pharmaceuticals during the 4th quarter worth approximately $25,000. Quadrant Capital Group LLC increased its holdings in Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after purchasing an additional 101 shares in the last quarter. CoreFirst Bank & Trust bought a new stake in Jazz Pharmaceuticals during the 4th quarter worth approximately $28,000. Allianz SE bought a new stake in Jazz Pharmaceuticals during the 4th quarter worth approximately $29,000. Finally, Jones Financial Companies Lllp increased its holdings in Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock worth $37,000 after purchasing an additional 130 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock traded up $0.25 during trading on Friday, hitting $108.07. The stock had a trading volume of 958,795 shares, compared to its average volume of 851,979. Jazz Pharmaceuticals plc has a 1 year low of $95.49 and a 1 year high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock's 50 day moving average is $112.87 and its two-hundred day moving average is $121.95. The stock has a market cap of $6.66 billion, a price-to-earnings ratio of 15.22, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). The company had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The company's revenue was down .5% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.68 EPS. As a group, analysts predict that Jazz Pharmaceuticals plc will post 16.96 EPS for the current year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 6,500 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $144.25, for a total transaction of $937,625.00. Following the sale, the chief executive officer now owns 464,058 shares in the company, valued at $66,940,366.50. This represents a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Seamus Mulligan bought 1,621 shares of the company's stock in a transaction on Monday, May 12th. The shares were bought at an average price of $103.00 per share, for a total transaction of $166,963.00. Following the transaction, the director now owns 101,621 shares of the company's stock, valued at approximately $10,466,963. This represents a 1.62% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 28,236 shares of company stock worth $3,956,190 over the last 90 days. Corporate insiders own 4.20% of the company's stock.

Wall Street Analyst Weigh In

JAZZ has been the subject of a number of recent research reports. JPMorgan Chase & Co. boosted their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Wall Street Zen lowered Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Royal Bank of Canada reduced their target price on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. UBS Group raised Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and upped their target price for the company from $145.00 to $179.00 in a report on Friday, March 7th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $182.79.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.